{"id":"W4310290800","doi":"10.1007/s10557-022-07392-2","title":"Safety and Efficacy of CYP2C19 Genotype-Guided Escalation of P2Y12 Inhibitor Therapy After Percutaneous Coronary Intervention in Chronic Kidney Disease: a Post Hoc Analysis of the TAILOR-PCI Study","year":2022,"lang":"en","type":"article","venue":"Cardiovascular Drugs and Therapy","topic":"Antiplatelet Therapy and Cardiovascular Diseases","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Ottawa; University Health Network; Toronto General Hospital; St. Michael's Hospital","funders":"Duke Clinical Research Institute; National Heart, Lung, and Blood Institute; National Institutes of Health; Regeneron Pharmaceuticals; Bayer Canada; Esperion Therapeutics; Servier; Novo Nordisk; Daiichi-Sankyo; Boston Scientific Corporation; Pfizer; York University; Eli Lilly and Company; Cleveland Clinic; Bristol-Myers Squibb; AstraZeneca; CSL Behring; Eli Lilly Canada; AstraZeneca Canada; University of Toronto; Heart and Stroke Foundation of Canada; American Regent; Sanofi; Amgen; HLS Therapeutics; U.S. Department of Health and Human Services","keywords":"Medicine; Percutaneous coronary intervention; Conventional PCI; Kidney disease; Internal medicine; Clinical endpoint; Renal function; Myocardial infarction; Post-hoc analysis; Cardiology; Randomized controlled trial; Population; P2Y12","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003649455,0.001558008,0.004813413,0.0003332607,0.0003060677,0.001324742,0.0007994971,0.001028113,0.002450882],"category_scores_gemma":[0.004021726,0.0004666427,0.003480028,0.0005717493,0.0008588171,0.001339366,0.0005945267,0.002500041,0.0003945322],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006291293,"about_ca_system_score_gemma":0.0008117108,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007604064,"about_ca_topic_score_gemma":0.001377605,"domain_scores_codex":[0.9971642,0.001626289,0.0001307575,0.0004996032,0.0002117081,0.0003674042],"domain_scores_gemma":[0.9968705,0.001337745,0.0006497132,0.000690499,0.0001494008,0.0003022807],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.9586461,0.002365526,0.01219637,0.0001925722,0.006191532,0.00006246434,0.00007702525,0.001338518,0.002504865,0.0001136878,0.0007167332,0.01559453],"study_design_scores_gemma":[0.4026835,0.2769661,0.2839634,0.00008041439,0.01831752,0.0001884266,0.0001964624,0.009482244,0.004678894,0.001360724,0.00184041,0.0002418812],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9973152,0.0006718328,0.0004375176,0.00009417801,0.00005938764,0.0001581281,0.0005437229,0.00005250782,0.0006673955],"genre_scores_gemma":[0.9973854,0.0002440498,0.0005059711,0.0001500404,0.0001433874,0.0001857407,0.0006365196,0.00002741541,0.0007214879],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004813413,"threshold_uncertainty_score":0.0193004,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.008144742595637439,"score_gpt":0.2386803708205855,"score_spread":0.2305356282249481,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}